A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Hemay022+AI|DRUG: Lapatinib+Capecitabine
Sponsor: Tianjin Hemay Oncology Pharmaceutical Co., Ltd